Precision Biosciences Aims for Key Clinical Data in 2026

Precision Biosciences US74019P2074

Precision Biosciences is directing its efforts toward achieving significant clinical milestones for its ARCUS gene-editing platform this year. The biotech firm is advancing two primary therapeutic candidates, targeting chronic Hepatitis B and Duchenne Muscular Dystrophy, with crucial data readouts anticipated. The central challenge for the company is whether forthcoming trial results can provide a durable foundation for its stock valuation.

From a financial perspective, the company reports a stable runway. As of the end of 2025, Precision Biosciences held approximately $137 million in cash and equivalents, which management states funds operations into 2028. This liquidity is further supported by partnership milestone payments, including an $8 million inflow received in the fourth quarter of 2025 related to a CAR-T therapy collaboration.

Despite this solid cash position, investor sentiment toward clinical-stage biotech stocks remains cautious, reflecting broader market trends. This is evident in the equity's performance, with shares touching a new 52-week low of €3.28 in recent trading.

• Current Share Price: €3.28
• 52-Week Low: €3.28 (recently reached)

Upcoming Clinical Catalysts

The clinical pipeline holds the key to near-term momentum. The most advanced candidate, PBGENE-HBV for chronic Hepatitis B, is currently being evaluated in the "ELIMINATE-B" study. Initial patient cohorts have been dosed, and the company has reported no dose-limiting toxicities to date. The next major catalyst is expected in the first half of 2026, when new biopsy data offering insights into antiviral activity are scheduled for release.

In parallel, the company is on the verge of initiating patient recruitment for its Duchenne Muscular Dystrophy program, PBGENE-DMD. Subject to regulatory clearance, dosing is projected to commence by late in the first quarter or early in the second quarter of 2026. Initial data from this study are projected by year-end.

Looking further ahead, management is scheduled to present additional portfolio details at the SOHO conference in September 2026. However, the interim release of the Hepatitis B biopsy data in the coming months is set to be the primary driver for assessing the company's clinical progress.